Saturday 17 October 2026
Export SNWV’s income statement to Excel — free account
Sanuwave Health Inc.
SNWV Healthcare Medical Devices
Sanuwave Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.1 million, up 35.0% from fiscal 2024. In the quarter to June 2026, revenue fell 3.13%, EPS fell 224.2%, free cash flow grew 86.8% and total debt fell 28.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
4.96
0.21
−4.06%
Follow SNWV
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 4 | 5 | 3 | 4 | 4 | 3 | 4 | 3 |
P/E ratio |
22.70 | 0.00 | 2.49 | 2.49 | 2.49 | 2.49 | 2.49 | 2.49 | 2.49 | 2.49 |
P/S ratio |
5.80 | 3.15 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 |
Altman Z-Score |
(2.97) | (10.06) | — | — | — | — | — | — | — | — |
P/FCF ratio |
34.96 | 52.24 | 117.92 | 117.92 | 117.92 | 117.92 | 117.92 | 117.92 | 117.92 | 117.92 |
Altman Z″-Score (non-manufacturers) |
(19.06) | (32.94) | (48.94) | (53.29) | (56.29) | (37.98) | (158.70) | (450.52) | (339.69) | (391.38) |
P/Operating CF |
76.99 | 138.52 | 32.38 | 32.38 | 32.38 | 32.38 | 32.38 | 32.38 | 32.38 | 32.38 |
Beneish M-Score |
(0.90) | (7.78) | (6.97) | (0.43) | (6.45) | 3.54 | (2.12) | (33.36) | (18.29) | (14.22) |
P/B ratio |
157.84 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
6.03 | 3.61 | 2.17 | 2.17 | 2.17 | 2.17 | 2.17 | 2.17 | 2.17 | 2.17 |
EV/EBITDA |
34.53 | 11.20 | 5.74 | 5.74 | 5.74 | 5.74 | 5.74 | 5.74 | 5.74 | 5.74 |
EV/Operating CF |
68.51 | 47.98 | 148.15 | 148.15 | 148.15 | 148.15 | 148.15 | 148.15 | 148.15 | 148.15 |
EV/FCF |
36.33 | 59.94 | 180.56 | 180.56 | 180.56 | 180.56 | 180.56 | 180.56 | 180.56 | 180.56 |
Quick Ratio |
0.97 | 0.30 | 0.08 | 0.09 | 0.05 | 0.13 | 0.15 | 0.04 | 0.08 | 0.08 |
Current Ratio |
1.38 | 0.41 | 0.15 | 0.11 | 0.08 | 0.22 | 0.20 | 0.07 | 0.11 | 0.12 |
Net Debt/EBITDA |
1.30 | 1.44 | 2.85 | (4.35) | (1.24) | (0.09) | 0.11 | (1.19) | (0.03) | 0.03 |
Debt/Assets |
58.81% | 84.24% | 101.95% | 72.54% | 67.77% | 19.39% | 23.64% | 460.12% | 64.58% | 4.72% |
Debt/Equity |
13.56 | (1.61) | (0.53) | (0.35) | (0.32) | (0.33) | (0.08) | (0.35) | (0.08) | (0.01) |
Asset Turnover |
1.31 | 1.24 | 0.96 | 0.87 | 0.62 | 0.31 | 0.45 | 1.51 | 0.65 | 1.40 |
Operating CF/Net income |
0.33 | (0.07) | 0.18 | 1.67 | 0.24 | 0.41 | 0.61 | 0.31 | 0.28 | 0.50 |
Capex/Depreciation |
1.25 | (0.07) | 0.00 | 0.06 | (0.12) | (0.04) | (0.76) | (0.01) | 0.00 | (0.02) |
Interest Coverage |
0.79 | 0.28 | (0.03) | (0.63) | (1.99) | (9.92) | (4.79) | (1.60) | (3.36) | (3.88) |
| (166.66%) | 112.20% | 61.31% | 25.74% | 103.50% | 260.18% | 82.06% | 92.18% | 65.96% | 100.69% | |
| 35.02% | (125.95%) | (122.05%) | (53.48%) | (130.91%) | (234.29%) | (457.48%) | (946.99%) | (484.99%) | (655.94%) | |
ROIC |
26.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
134.97% | 123.80% | 47.76% | 19.52% | 53.61% | 111.38% | 106.24% | 75.89% | 55.97% | 92.98% |
Average Days of Receivables |
44.93 | 37.23 | 59.30 | 87.84 | 67.75 | 211.96 | 26.79 | 46.32 | 75.37 | 122.22 |
Research and Development Expense of Revenue |
3.07% | 2.06% | 2.84% | 3.39% | 8.46% | 30.71% | 114.89% | 53.06% | 175.02% | 82.01% |
Selling, General and Administrative Expense of Revenue |
60.82% | 58.96% | 66.54% | 119.64% | 155.89% | 465.44% | 780.70% | 396.34% | 406.82% | 194.30% |
Intangible Assets out of Total Assets |
0.28 | 0.36 | 0.52 | 0.62 | 0.70 | 0.60 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
11.01% | 4.64% | 1.10% | 5.30% | 0.00% | 64.41% | 35.18% | 188.70% | 129.86% | 56.52% |
Graham Net Nets |
(0.04) | (0.27) | (1.74) | (1.74) | (1.74) | (1.74) | (1.74) | (1.74) | (1.74) | (1.74) |
Graham Number |
2.36 | 23.58 | 71.41 | 66.12 | 110.45 | 94.38 | 87.02 | 155.68 | 93.37 | 109.05 |
Earnings Yield |
4.40% | (30.35%) | 40.22% | 40.22% | 40.22% | 40.22% | 40.22% | 40.22% | 40.22% | 40.22% |
Free Cash Flow Yield |
2.86% | 1.91% | 0.85% | 0.85% | 0.85% | 0.85% | 0.85% | 0.85% | 0.85% | 0.85% |
Revenue per Share |
5.14 | 7.31 | 9.64 | 11.28 | 9.30 | 3.97 | 1.87 | 4.58 | 1.97 | 4.74 |
Operating CF per Share |
0.45 | 0.55 | (2.14) | (11.57) | (4.58) | (12.46) | (11.66) | (8.97) | (4.08) | (11.01) |
Capex per Share |
0.40 | (0.11) | 0.01 | 0.22 | (0.38) | (0.05) | (0.10) | (0.11) | 0.00 | (0.03) |
Free Cash Flow per Share |
0.85 | 0.44 | (2.13) | (11.35) | (4.96) | (12.51) | (11.76) | (9.07) | (4.08) | (11.04) |
Cash per Share |
1.40 | 2.29 | 0.85 | 0.78 | 0.44 | 2.39 | 3.20 | 0.90 | 1.95 | 0.46 |
Shareholders Equity per Share |
0.19 | (3.54) | (20.40) | (27.64) | (27.84) | (13.44) | (18.31) | (38.03) | (26.36) | (23.78) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.19 | (3.54) | (20.40) | (27.64) | (27.84) | (13.44) | (18.31) | (38.03) | (26.36) | (23.78) |
Free Cash Flow |
7.31 | 1.97 | (4.52) | (16.84) | (6.94) | (12.77) | (6.46) | (3.66) | (1.53) | (3.21) |
Working Capital |
6.78 | (27.03) | (54.97) | (53.59) | (51.86) | (28.25) | (9.91) | (15.40) | (9.96) | (7.00) |
Capital Expenditures |
3.43 | (0.49) | 0.02 | 0.33 | (0.53) | (0.05) | (0.05) | (0.04) | — | (0.01) |
Net Current Asset Value |
(11.10) | (27.52) | (55.81) | (54.26) | (53.18) | (28.82) | (10.94) | (15.45) | (9.96) | (7.00) |
EV/EBIT |
53.70 | 30.61 | 16.16 | 16.16 | 16.16 | 16.16 | 16.16 | 16.16 | 16.16 | 16.16 |
Capex to Sales |
(0.08) | 0.02 | 0.00 | (0.02) | 0.04 | 0.01 | 0.05 | 0.02 | 0.00 | 0.01 |
Price to Operating Income |
51.68 | 26.68 | 10.55 | 10.55 | 10.55 | 10.55 | 10.55 | 10.55 | 10.55 | 10.55 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.39 | 22.00 | 8.46 | 6.89 | 4.41 | 3.18 | 0.76 | 37.79 | 9.36 | 7.59 |
Cash ROIC |
20.57% | 9.92% | 24.38% | 66.18% | 26.98% | 187.34% | 86.16% | 38.28% | 18.37% | 47.67% |
Accounts Receivable Turnover |
10.07 | 9.83 | 5.56 | 5.20 | 5.45 | 3.34 | 6.63 | 9.55 | 2.41 | 5.14 |
Accounts Payable Turnover |
2.89 | 1.71 | 1.19 | 0.72 | 0.82 | 0.39 | 0.36 | 0.45 | 0.22 | 0.92 |
Inventory Turnover |
2.00 | 2.28 | 3.16 | 4.54 | 2.50 | 0.66 | 1.20 | 2.35 | 1.04 | 2.19 |
Average Days of Payables |
117.70 | 168.32 | 345.04 | 370.82 | 559.58 | 1,399.06 | 974.91 | 837.97 | 2,257.12 | 460.53 |
Days of Inventory on Hand |
214.83 | 187.33 | 178.48 | 73.15 | 76.13 | 928.52 | 367.78 | 188.26 | 349.16 | 149.85 |
Average Receivables |
4.38 | 3.32 | 3.67 | 3.22 | 2.39 | 1.22 | 0.16 | 0.19 | 0.31 | 0.27 |
Average Payables |
3.49 | 4.72 | 5.05 | 6.02 | 6.05 | 2.95 | 1.52 | 1.54 | 1.10 | 0.61 |
Average Inventory |
5.04 | 3.55 | 1.91 | 0.95 | 2.00 | 1.75 | 0.45 | 0.29 | 0.23 | 0.26 |
Average Assets |
33.73 | 26.27 | 21.14 | 19.25 | 20.82 | 13.20 | 2.28 | 1.23 | 1.14 | 0.98 |
Average Common Equity |
(7.09) | (29.49) | (42.09) | (39.98) | (26.34) | (11.89) | (12.71) | (12.62) | (8.40) | (6.39) |
Columns are period end dates